{"id":424,"date":"2020-03-16T18:17:34","date_gmt":"2020-03-16T18:17:34","guid":{"rendered":"https:\/\/www.doctaforum-events.org\/2025\/emma2025\/?page_id=424"},"modified":"2025-08-27T06:40:15","modified_gmt":"2025-08-27T06:40:15","slug":"friday-september-5","status":"publish","type":"page","link":"https:\/\/www.doctaforum-events.org\/2025\/emma2025\/friday-september-5\/","title":{"rendered":"Friday, September 5"},"content":{"rendered":"

<\/p>\n

\n
\n
\n
\n

09:00 – 09:10<\/h4>\n<\/div>\n
\n

Opening<\/h4>\n<\/div>\n<\/div>\n
\n\n\n\n\t
Jes\u00fas F. San-Miguel <\/span>
\nHeinz Ludwig<\/span>
\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
\n
\n
\n

09:10 – 10:25<\/h4>\n<\/div>\n
\n

PLENARY SESSION 1: MYELOMA BIOLOGY<\/h4>\n<\/div>\n<\/div>\n
\n\n\n\n\t\n\t\n\t\n\t\n\t\n\t
Moderator<\/span><\/td>Felipe Pr\u00f3sper <\/span><\/td>\n<\/tr>\n
09:10 - 09:30<\/td>How is the transition from MGUS into MM?<\/span>
\nBruno Paiva<\/span><\/td>\n<\/tr>\n
09:30 - 09:50<\/td>What should I know about systemic manifestations in MGUS patients?<\/span>
\nJoan Blad\u00e9<\/span><\/td>\n<\/tr>\n
09:50 - 10:10<\/td>Can we identify and treat high risk Smoldering Myeloma patients?<\/span>
\nDr. Karthik Ramasamy<\/span><\/td>\n<\/tr>\n
10:10 - 10:25<\/td>Experts' discussion around 5 burning questions:<\/span>
\n

    \n
  1. 1. What is the meaning of genetic and epigenetic changes in MGUS and SMM?<\/span><\/li>
    \n
  2. 2. When to atribute clinical manifestations to the M-component?<\/span><\/li>
    \n
  3. 3. Optimal treatment in MGUS with renal impairment<\/span><\/li>
    \n
  4. 4. How to define High Risk SMM?<\/span><\/li>
    \n
  5. 5. To treat or no to treat SMM<\/span><\/li>
    \n<\/ol><\/td>\n<\/tr>\n
<\/td>Discussants: Dr. Pr\u00f3sper, Dr. Paiva, Dr. Blad\u00e9, Dr. Ramasamy, Dr. Ludwig, Dr. San-Miguel<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
\n
\n
\n

10:25 – 10:45<\/h4>\n<\/div>\n
\n

Break<\/h4>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n

10:45 – 12:00<\/h4>\n<\/div>\n
\n

PLENARY SESSION 2: NEW TOOLS FOR PROGNOSTICATION AND MONITORING IN MM<\/h4>\n<\/div>\n<\/div>\n
\n\n\n\n\t\n\t\n\t\n\t\n\t\n\t
Moderator<\/span><\/td>Heinz Ludwig<\/span><\/td>\n<\/tr>\n
10:45 - 11:05<\/td>Genomics in myeloma?: new tools and new definitions.<\/span>
\nHerve Avet-Loiseau<\/span><\/td>\n<\/tr>\n
11:05 - 11:25<\/td>Why MRD should be implemented in trials and routine practice? to whom, when and with which technique?<\/span>
\nNoem\u00ed Puig<\/span><\/td>\n<\/tr>\n
11:25 - 11:45<\/td>Should I use CT, MRI or CT-PET?<\/span>
\nElena Zamagni<\/span><\/td>\n<\/tr>\n
11:45 - 12:00<\/td>Experts' discussion around 5 burning questions:<\/span>
\n

    \n
  1. 1. Optimal techniques for genetics<\/span><\/li>
    \n
  2. 2. Optimal MRD technique<\/span><\/li>
    \n
  3. 3. Prognostic factors or biomarker for treatment<\/span><\/li>
    \n
  4. 4. Should we stratify patients?<\/span><\/li>
    \n
  5. 5. Should we implement PET in routine clinical practice?<\/span><\/li>
    \n<\/ol><\/td>\n<\/tr>\n
<\/td>Discussants: Dr. Ludwig, Dr. Avet-Loiseau, Dr. Puig, Dr. Zamagni, Dr. Manier, Dr. Paiva, Dr. Terpos<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
\n
\n
\n

12:00 – 13:15<\/h4>\n<\/div>\n
\n

PLENARY SESSION 3: CHALLENGING TOPICS<\/h4>\n<\/div>\n<\/div>\n
\n\n\n\n\t\n\t\n\t\n\t\n\t
Moderator<\/span><\/td>Jes\u00fas F. San-Miguel<\/span><\/td>\n<\/tr>\n
12:00 - 12:20<\/td>Emergencies and supportive care (cord compression, RI, bone disease)<\/span>
\nEvangelos Terpos<\/span><\/td>\n<\/tr>\n
12:20 - 12:40<\/td>What are the clues for difficult to treat MM (extramedullary, CNS, solitary)?<\/span>
\nKwee Yong<\/span><\/td>\n<\/tr>\n
12:40 - 13:00<\/td>How to deal with immunotherpy adverse events<\/span>
\nCyrille Touzeau<\/span><\/td>\n<\/tr>\n
13:00 - 13:15<\/td>Questions & discussion<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
\n
\n
\n

13:15 – 14:00<\/h4>\n<\/div>\n
\n

Lunch<\/h4>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n

14:00 – 14:30<\/h4>\n<\/div>\n
\n

PLENARY SESSION 4: KEYNOTE LECTURE<\/h4>\n<\/div>\n<\/div>\n
\n\n\n\n\t\n\t\n\t
Moderator<\/span><\/td>Jes\u00fas F. San-Miguel<\/span><\/td>\n<\/tr>\n
14:00 - 14:20<\/td>How to prevent and treat infections in myeloma<\/span>
\nHeinz Ludwig<\/span><\/td>\n<\/tr>\n
14:20 - 14:30<\/td>Questions & discussion<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
\n
\n
\n

14:30 – 15:45<\/h4>\n<\/div>\n
\n

PLENARY SESSION 5: FRONT LINE TREATMENT FOR YOUNG PATIENTS WITH MM<\/h4>\n<\/div>\n<\/div>\n
\n\n\n\n\t\n\t\n\t\n\t\n\t\n\t
Moderator<\/span><\/td>Jes\u00fas F. San-Miguel<\/span><\/td>\n<\/tr>\n
14:30 - 14:50<\/td>Is there an optimal induction? Transplant for all?<\/span>
\nElias Mai<\/span><\/td>\n<\/tr>\n
14:50 - 15:10<\/td>What type of consolidation and maintenance is recommended?<\/span>
\nPieter Sonneveld<\/span><\/td>\n<\/tr>\n
15:10 - 15:30<\/td>How to approach high-risk patients?<\/span>
\nMartin Kaiser<\/span><\/td>\n<\/tr>\n
15:30 - 15:45<\/td>Experts' discussion around 5 burning questions:<\/span>
\n

    \n
  1. 1. Best induction<\/span><\/li>
    \n
  2. 2. Early vs. late transplant<\/span><\/li>
    \n
  3. 3. One vs. two<\/span><\/li>
    \n
  4. 4. Consolidation & maintenance<\/span><\/li>
    \n
  5. 5. High risk<\/span><\/li>
    \n<\/ol><\/td>\n<\/tr>\n
<\/td>Discussants: Dr. San-Miguel, Dr. Mai, Dr. Sonneveld, Dr. Kaiser, Dr. Blad\u00e9, Dr. Touzeau<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
\n
\n
\n

15:45 – 16:05<\/h4>\n<\/div>\n
\n

Break<\/h4>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n

16:05 – 17:00<\/h4>\n<\/div>\n
\n

PLENARY SESSION 6: FRONT LINE TREATMENT FOR ELDERLY PATIENTS WITH MM<\/h4>\n<\/div>\n<\/div>\n
\n\n\n\n\t\n\t\n\t\n\t\n\t
Moderator<\/span><\/td> Heinz Ludwig<\/span><\/td>\n<\/tr>\n
16:05 - 16:25<\/td>How should I treat elderly patients?<\/span>
\nSalomon Manier<\/span><\/td>\n<\/tr>\n
16:25 - 16:45<\/td>How should I treat elderly frail patients?<\/span>
\nAlessandra Larocca<\/span><\/td>\n<\/tr>\n
16:45 - 17:00<\/td>Experts' discussion around 5 burning questions:<\/span>
\n

    \n
  1. 1. Optimal combination and duration<\/span><\/li>
    \n
  2. 2. Maintenance\/continuous<\/span><\/li>
    \n
  3. 3. Do we need alkylators?<\/span><\/li>
    \n
  4. 4. High risk<\/span><\/li>
    \n
  5. 5. Frailty<\/span><\/li>
    \n<\/ol><\/td>\n<\/tr>\n
<\/td>Discussants: Dr. Ludwig, Dr. Manier, Dr. Larocca, Dr. Delforge, Dr. Ramasamy<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

09:00 – 09:10 Opening 09:10 – 10:25 PLENARY SESSION 1: MYELOMA BIOLOGY 10:25 – 10:45 Break 10:45 – 12:00 PLENARY SESSION 2: NEW TOOLS FOR PROGNOSTICATION AND MONITORING IN MM 12:00 – 13:15 PLENARY SESSION 3: CHALLENGING TOPICS 13:15 – 14:00 Lunch 14:00 – 14:30 PLENARY SESSION 4: KEYNOTE LECTURE 14:30 – 15:45 PLENARY SESSION […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-424","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.doctaforum-events.org\/2025\/emma2025\/wp-json\/wp\/v2\/pages\/424"}],"collection":[{"href":"https:\/\/www.doctaforum-events.org\/2025\/emma2025\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.doctaforum-events.org\/2025\/emma2025\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.doctaforum-events.org\/2025\/emma2025\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.doctaforum-events.org\/2025\/emma2025\/wp-json\/wp\/v2\/comments?post=424"}],"version-history":[{"count":94,"href":"https:\/\/www.doctaforum-events.org\/2025\/emma2025\/wp-json\/wp\/v2\/pages\/424\/revisions"}],"predecessor-version":[{"id":1573,"href":"https:\/\/www.doctaforum-events.org\/2025\/emma2025\/wp-json\/wp\/v2\/pages\/424\/revisions\/1573"}],"wp:attachment":[{"href":"https:\/\/www.doctaforum-events.org\/2025\/emma2025\/wp-json\/wp\/v2\/media?parent=424"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}